Alexis Borisy is a successful biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Mr. Borisy joined the life sciences venture capital firm Third Rock Ventures in 2009 to focus on the formation of new companies. He co-founded Foundation Medicine and served as the company’s first CEO and currently as its Chairman, co-founded Blueprint Medicines, and launched and is serving as interim CEO of Warp Drive Bio. Prior to joining Third Rock Ventures, Mr. Borisy founded CombinatoRx in 2000, serving as its Chief Executive Officer and bringing the company public on the NASDAQ. He has raised more than $1b in financing and business development deals, and has authored numerous scientific papers and patents.
Mr. Borisy was... Read More.
Niall Brennan is the Director in the Policy and Data Analysis Group in the Center for Strategic Planning at the Centers for Medicare and Medicaid Services where he oversees a range of activities related to the overall strategic goals of the agency. The office performs a variety of analyses on high profile issues on a quick turnaround basis, to the CMS administrator, senior leaders and other HHS department leaders.
Prior to joining CMS, Brennan directed the Characterizing Episodes and Costs of Care (C3) project, a joint Brookings Institution/American Board of Medical Specialties initiative to develop a starter set of fully transparent, episode-based cost-of-care measures that is funded by the Robert Wood Johnson Foundation, conducted research related to comparisons of quality between the... Read More.
Tina Brown-Stevenson is the Senior Vice President, Healthcare Analytics & Decision Support at UnitedHealthcare. In 2010, her contributions to health care earned her national recognition in the annual “Women Worth Watching” issue of Profiles in Diversity Journal, an issue dedicated to highlighting women leaders who make a difference.
Previously, Brown-Stevenson was the executive vice president of the Health Care Innovation and Information Group at OptumInsight. Before joining OptumInsight, Brown-Stevenson was president and head of Aetna Informatics, Aetna’s data, information, and analytics subsidiary responsible for statistical modeling, plan sponsor reporting, data warehousing, and analytical product development. Prior to joining Aetna in 2001, Brown-Stevenson served as the vice president of HealthCare Economics at Cigna, as vice president of Health System Development at Partners Healthcare System in Boston,... Read More.
As a founder, chief visionary officer and chair of the board at Eliza Corporation, the pioneer and recognized leader in Health Engagement Management, Alexandra Drane has proven herself as a visionary, whose ideas on using technology to engage people in their health – and her belief in adding a touch of joy to the often staid world of healthcare communications – have been adopted by the nation’s top healthcare organizations, with resulting outcomes such as:
•Increasing the rate of childhood immunizations in underserved areas by 30 percent over a three-year period (This project was acknowledged at the Center for Disease Control’s 41st National Immunization Conference in March, 2007 for the Most Improved Award for Urban Areas)
•Saving health plan members $11 million over the course... Read More.
David Ewing Duncan is an award-winning, best-selling author of eight books published in 19 languages; he is a journalist and a television, radio and film producer and correspondent. His most recent book is When I’m 164: The new science of radical life extension, and what happens if it succeeds(TED Books). He is a Correspondent for The Atlantic, and the Chief Correspondent of public radio’s Biotech Nation, heard on NPR Talk. David writes for The New York Times, Fortune , Wired, National Geographic, Discover, Atlantic Monthly, and many other publications. He is the Founding Director of the Center of Life Science Policy at UC Berkeley, and the Director of the Personalized Health Project. He has been a commentator on NPR’s Morning Edition, and a... Read More.
Dr. Friend is the President of Sage Bionetworks. He is an authority in the field of cancer biology and a leader in efforts to make large scale, data-intensive biology broadly accessible to the entire research community. Dr. Friend has been a senior advisor to the NCI, several biotech companies, a Trustee of the AACR and is a AAAS and Ashoka Fellow as well as an editorial board memeber of Open Network Biology. Dr. Friend was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center’s Seattle Project, an advanced... Read More.
An MIT engineer, Jamie entered the field of translational research and medicine when his
brother Stephen was diagnosed with ALS in 1998 at the age of 29. With experience in design,
information technology, systems modeling, neuroscience and industrial engineering, Jamie
brings a unique perspective to drug discovery and medicine. The scientific and business
innovations he developed at ALS TDI and PatientsLikeMe have been transforming the
intersection of biotechnology and pharmaceutical development, personalized medicine, and
Currently, Jamie serves as chairman of PatientsLikeMe, where he provides the scientific vision
and architecture for its patient-centered medical platform. He co-founded the company in 2005
with his youngest... Read More.
Colin is a frequent speaker at international scientific and industry conferences and has appeared in numerous publications and television segments including The Wall Street Journal, CNBC Morning Call, Nature, Forbes, Wired, and The Economist. He serves as CEO and Chairman of GNS Healthcare’s parent company Via Science, and chairman of the board of Fina Technologies, a subsidiary of Via Science that applies next-generation artificial intelligence technology to real-time financial trading. He also serves on the board of directors of AesRx, a biopharmaceutical company dedicated to the development of a new treatment for sickle cell disease.
In 2004, Colin was named to MIT Technology Review’s TR100 list of the top innovators in the world under the age of 35.... Read More.
Dr. Hood is a pioneer in the systems approach to biology and medicine. His research has focused on the study of molecular immunology, biotechnology and genomics. Dr. Hood’s professional career began at Caltech, where he and his colleagues developed the DNA gene sequencer and synthesizer and the protein synthesizer and sequencer––four instruments that paved the way for the successful mapping of the human genome. A pillar in the biotechnology field, Dr. Hood has played a role in founding more than fourteen biotechnology companies, including Amgen, Applied Biosystems, Darwin, The Accelerator and Integrated Diagnostics. He is a member of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. Of the 6,000+ scientists world-wide who belong to one or more... Read More.
Vinod Khosla is an entrepreneur, investor, and technology fan. He is the founder of Khosla Ventures, focused on impactful clean technology and information technology investments. Mr. Khosla was a co-founder of Daisy systems and founding CEO of Sun Microsystems where he pioneered open systems and commercial RISC processors. One of Mr. Khosla’s greatest passions is being a mentor to entrepreneurs, assisting entrepreneurs and helping them build technology based businesses. Mr. Khosla is driven by the desire to make positive impact through scaling alternative energy, achieving petroleum independence, and promoting a pragmatic approach to the environment. He is also passionate about Social Entrepreneurship. Vinod holds a Bachelor of Technology in Electrical Engineering from IIT, New Delhi, a Master’s in Biomedical Engineering from... Read More.
Andrew Kress is senior vice president, Healthcare Value Solutions for IMS Health. In this role, he leads IMS initiatives that connect healthcare stakeholders through real-world evidence to demonstrate the value of medicines, enhance quality and drive improved outcomes. Andrew is responsible for a portfolio of growth platforms, including IMS’s Health Economics and Outcomes Research, Clinical Trial Optimization Services, Government Solutions and, Payer and Provider Solutions businesses.
Andrew joined IMS in 2011 with the acquisition of SDI Health, a leading U.S.-based healthcare market insights and analytics firm, where he served as president and CEO since 2006. In this role, Andrew led the company’s expansion from primary market research into the longitudinal patient-level data space, guided product development activities and advanced relationships... Read More.
Carol McCall is a health actuary with a background in innovation, predictive analytics and health services design. Her specialties are creating novel computational approaches that leverage ‘big data’ in healthcare, and designing services and business models that expand the traditional notions of health, care, community and sustainability.
Carol is the Chief Strategy Officer for GNS Healthcare, a Big Data Analytics company whose industrialized knowledge discovery platform extracts cause-effect relationships directly and at scale from observational data. Her personal goal is to leverage these capabilities to redesign the entire notion of ‘evidence’ and ignite a true learning system in the healthcare system.
Prior to joining GNS Healthcare, Carol was Chief Innovation Officer for Tenzing Health, a subsidiary of Vanguard Health Systems, where she merged... Read More.
Blackford Middleton is Corporate Director of Clinical Informatics Research & Development (CIRD) at Partners Healthcare System, Boston, and Assistant Professor of Medicine at Brigham and Women’s Hospital, Harvard Medical School, and a Lecturer in Health Policy and Management at the Harvard School of Public Health. He is adjunct faculty at the Technische Universität München, Graduate School of Information Science in Health, Munich, Germany, and the Clinical Excellence Research Center at Stanford University.
As Corporate Director for CIRD, he leads the groups responsible for developing Partners enterprise clinical informatics infrastructure development, software product design for the Partners EMR and patient portal, enterprise clinical decision support and knowledge management services, and conducts clinical informatics research. In 2004 CIRD joined the National Library of... Read More.
Tim has a history of convening conversations that reshape the industry. In 1998, he organized the meeting where the term “open source software” was agreed on, and helped the business world understand its importance. In 2004, with the Web 2.0 Summit, he defined how “Web 2.0” represented not only the resurgence of the web after the dot com bust, but a new model for the computer industry, based on big data, collective intelligence, and the internet as a platform. In 2009, with his “Gov 2.0 Summit,” he framed a conversation about the modernization of government technology that has shaped policy and spawned initiatives at the Federal, State, and local level, and around the world. He has now turned his attention to implications of the on-demand... Read More.
Dr. Eric Schadt recently joined Mount Sinai Medical School as Chairman and Professor, Department of Genetics and Genomic Sciences and as Director, Institute of Genomics and Multiscale Biology in 2011. Previously, Dr. Schadt had been the Chief Scientific Officer at Pacific Biosciences, overseeing the scientific strategy for the company, including creating the vision for next-generation sequencing applications of the company’s technology. Dr. Schadt is also a founding member of Sage Bionetworks, an open access genomics initiative designed to build and support databases and an accessible platform for creating innovative, dynamic models of disease. Dr. Schadt’s current efforts at Mount Sinai to generate and integrate large-scale, high-dimension molecular, cellular, and clinical data to build more predictive models of disease so that we may better diagnose and... Read More.
Bill Schmarzo, author of the upcoming “Big Data: Understanding How Data Powers Big Business” to be published by Wiley, is responsible for setting the strategy and defining the service line offerings and capabilities for the EMC Consulting Enterprise Information Management and Analytics service line. He’s written several white papers and is a frequent speaker on the use of Big Data and advanced analytics to power organization’s key business initiatives.
Bill has more than two decades of experience in data warehousing, BI and analytic applications. Bill authored the Business Benefits Analysis methodology that links an organization’s strategic business initiatives with their supporting data and analytic requirements, and co-authored with Ralph Kimball a series of articles on analytic applications. Bill has served on The Data Warehouse... Read More.
Julie Steele is an editor at O’Reilly Media interested in connecting people and ideas. She finds beauty in discovering new ways to understand complex systems, and so enjoys topics related to gathering, storing, analyzing, and visualizing data. She holds a Master’s degree in Political Science (International Relations) from Rutgers University.
Julie also works with topics related to the languages Python, PHP and SQL, and is co-founder of a group of non-programmers learning Python. Julie lives in NYC where she eats, reads, codes, and practices yoga.
Fred Trotter is a hacktivist, coding for social change. Trotter is one of the most celebrated health IT and health IT security experts in the country. He is one of the designers of the Direct Project, which is now a mandated health information exchange protocol in the United States. He, along with David Uhlman, wrote the first Health IT book for O’Reilly and the most popular book on the Meaningful Use standards: Meaningful Use and Beyond. Fred is always looking for ways to use to technology to empower patients to get better healthcare.
Ajay Verma studied zoology at the University of Maryland and received his MD and PhD from The Johns Hopkins University. His neuroscience training was in the laboratory of Dr. Soloman Snyder. His neurology training was at the Walter Reed Army Medical Center where he was a staff Neurologist for 11 years. He was also a tenured Professor in Neurology, and Neuroscience at the Uniformed Service University of the Health Sciences, the US Military’s Medical School. Since leaving the Army as a Lt. Colonel in 2006, Ajay has worked at Merck & Co., Inc. and Novartis Pharmaceuticals. He is currently Global Vice President at Biogen Idec for Neurology and Experimental Medicine.
John Wilbanks works on open content, open data, and open innovation systems. He is a Senior Fellow at the Kauffman Foundation and a Research Fellow at Lybba. He’s worked at Harvard Law School, MIT’s Computer Science and Artificial Intelligence Laboratory, the World Wide Web Consortium, the US House of Representatives, and Creative Commons, as well as starting a bioinformatics company. He sits on the Board of Directors for Sage Bionetworks, iCommons, and 1DegreeBio, and the Advisory Board for Boundless Learning. John holds a degree in philosophy from Tulane University and also studied modern letters at the University of Paris (La Sorbonne).
Anne brings to 23andMe a 10-year background in healthcare investing,
focused primarily on biotechnology companies. Anne left the investing
world with the hope that she could have a positive impact on research and
medicine through 23andMe. From her vantage point, Anne saw a need for
creating a way to generate more information – especially more
personalized information – so that commercial and academic researchers
could better understand and develop new drugs and diagnostics. By
encouraging individuals to access and learn about their own genetic
information, 23andMe will create a common, standardized resource that
has the potential to accelerate drug discovery and bring personalized
medicine to the public. (Plus, getting access to her own genetic information
For information on exhibition and sponsorship opportunities at the conference, contact Sharon Pierce at (203) 304-9476 or firstname.lastname@example.org
For information on trade opportunities with O'Reilly conferences contact mediapartners
For media-related inquiries, contact Maureen Jennings at email@example.com
View a complete list of Strata Rx contacts